Notably, AIM2 exerts anti-tumorigenic effects in colon cancer (Choubey, 2016), nasopharyngeal carcinoma (Chen et al., 2012), and prostate cancer (Ponomareva et al., 2013), and pro-tumorigenic effects in cutaneous squamous carcinoma (Farshchian et al., 2017), HPV-associated cervical cancer (Milutin Gašperov et al., 2014), and non-small cell lung cancer (Kong et al., 2015). This evidence concerns the gene AIM2 and non-small cell lung carcinoma.